BioVentrix Advances Its Revivent-TC Ventricular Enhancement Technology For Heart Failure
Executive Summary
BioVentrix Inc. has its sights set on US market approval for its hybrid transthoracic-endovascular Revivent-TC system, a unique device that enables a minimally invasive approach to treating patients who develop ischemic heart failure following a heart attack.